Paclitaxel nanoformulation- Nanology

Drug Profile

Paclitaxel nanoformulation- Nanology

Alternative Names: NanoPac

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Nanology
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer

Most Recent Events

  • 21 Jun 2017 NanOlogy plans a phase II trial for Pancreatic neoplasms (NCT03188991)
  • 12 Apr 2017 Phase-II clinical trials in Ovarian cancer (Late-stage disease) in USA (Intraperitoneal) (NCT03029585)
  • 15 Mar 2017 Nanology in collaboration with US Biotest plans a phase II trial for Pancreatic cancer in USA (NCT03077685)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top